Trials / Unknown
UnknownNCT02074241
Molecular Markers of Chemosensitivity for Bladder Cancer
Molecular Markers of Chemosensitivity for Locally Advanced, Recurrent and Metastatic Bladder Cancer Based on the Adjuvant Chemotherapy of Gemcitabine and Cisplatin-a Prospective Control Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Southwest Hospital, China · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to try to figure out some bio-markers of chemosensitivity for adjuvant chemotherapy for bladder cancer.
Detailed description
Figure out some bio-markers of chemosensitivity for adjuvant chemotherapy for bladder cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Expression analysis | Analysis of the expression of DNA repair genes (XPC, XPF, Brca1, Rad51,SNF5, etc.) in bladder cancer specimens. |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2019-04-01
- Completion
- 2019-04-01
- First posted
- 2014-02-28
- Last updated
- 2014-02-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02074241. Inclusion in this directory is not an endorsement.